Sanofi: Stronger Launches And A New R&D Reset Keep The Re-Rating Case Alive (NASDAQ:SNY)

seekingalpha.com · 2026-09-16

Sanofi Q2 raises guidance as Dupixent drives 2026 outlook; faster launches diversify revenue.